Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum
- PMID: 626972
Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum
Abstract
We studied the effects of intratumor injection of Corynebacterium parvum vaccine on the survival of 13762A tumor-bearing rats. Vaccine injection of established (7-day-old) tumors produced dose-related prolongation of survival and cured some animals. Although 30 to 40% of the vaccine-injected primary tumors regressed, recurrences and continued growth of metastases ultimately killed one-fourth of the regressors. Rats given 1500 microgram of C. parvum intratumorally at 7 days, with or without later primary tumor excision at 20 days were cured at a rate of 10 to 40%. Repeated injections improved the results (60%). C. parvum injections delayed until 12 and 17 days were ineffective. Cured rats were immune to rechallenge with 13762A tumor.
Similar articles
-
Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma.Cancer Res. 1979 Mar;39(3):987-92. Cancer Res. 1979. PMID: 427785
-
Destruction of regional lymph node metastases of rat mammary adenocarcinoma 13762A by treatment with Corynebacterium parvum.Cancer Res. 1978 Dec;38(12):4522-6. Cancer Res. 1978. PMID: 719637
-
Role of T-cell subsets in the destruction of established metastases of 13762A rat mammary adenocarcinoma.J Natl Cancer Inst. 1986 Jul;77(1):187-93. J Natl Cancer Inst. 1986. PMID: 3487670
-
Corynebacterium parvum as an immunotherapeutic anticancer agent.Semin Oncol. 1974 Dec;1(4):367-78. Semin Oncol. 1974. PMID: 4620441 Review. No abstract available.
-
Multimodal immunotherapy of primary gastrointestinal tumors in rats. 1. Histologic correlation.Cancer. 1978 Nov;42(5):2079-96. doi: 10.1002/1097-0142(197811)42:5<2079::aid-cncr2820420502>3.0.co;2-0. Cancer. 1978. PMID: 363250 Review.
Cited by
-
Histopathological modifications following immunotherapy with P 40 in rats bearing DMBA-induced mammary carcinoma.Experientia. 1980 Oct 15;36(10):1213-5. doi: 10.1007/BF01976136. Experientia. 1980. PMID: 6774883